-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ubidecarenone in Brain Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ubidecarenone in Brain Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ubidecarenone in Brain Cancer Drug Details: Ubidecarenone is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-103 in Brain Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-103 in Brain Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-103 in Brain Cancer Drug Details: MB-103 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Paxalisib in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paxalisib in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paxalisib in Metastatic Brain Tumor Drug Details: Paxalisib is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azeliragon in Refractory Brain Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azeliragon in Refractory Brain Metastasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azeliragon in Refractory Brain Metastasis Drug Details: Azeliragon is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Metastatic Brain Tumor Drug Details: Elzovantinib (TPX-0022) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neratinib in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Metastatic Brain Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neratinib in Metastatic Brain Tumor Drug Details: Neratinib (Nerlynx) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-212 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-212 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NEO-212 in Metastatic Brain Tumor Drug Details: NEO-212 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amantadine Hydrochloride in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amantadine Hydrochloride in Traumatic Brain Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amantadine Hydrochloride in Traumatic Brain Injury Drug Details: Amantadine hydrochloride...
-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...